<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097352</url>
  </required_header>
  <id_info>
    <org_study_id>PROJECT00004322</org_study_id>
    <nct_id>NCT05097352</nct_id>
  </id_info>
  <brief_title>Effects of a Short-term Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial</brief_title>
  <official_title>Effects of a High-intensity Interval Training (HIIT) Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Georgia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test whether sleep improvements, following 6 weeks of high-intensity&#xD;
      interval training exercise among adult women exposed to a traumatic event, are mediated by&#xD;
      improvements in heart rate variability or decreased anxiety and hyperarousal symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 60 women with below-average sleep quality and physical activity levels who also&#xD;
      screen positive for PTSD on the Post-traumatic Diagnostic Scale (PDS-5) will be randomized to&#xD;
      either six weeks of exercise training or a waitlist control. Twenty minutes of high intensity&#xD;
      interval training will be performed three times per week for six-weeks. Heart rate&#xD;
      variability will be measured at rest, during, and following a cognitive task. Psychometric&#xD;
      measures supported by strong validity evidence will assess self-reported anxiety and PTSD&#xD;
      symptoms, and sleep quality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburg Sleep Quality Index (PSQI)</measure>
    <time_frame>Change from Baseline to week 7</time_frame>
    <description>The PSQI consists of 19 items. Scores range from 0-21, higher scores indicate poorer sleep quality. A global score â‰¥5 indicates poor sleep quality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>Change from Baseline to Week 7</time_frame>
    <description>High frequency (HF) and low frequency (LF) domains of heart rate variability will be assessed before, during, and following a cognitive task.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>State Trait Anxiety Inventory (STAI-Y2)</measure>
    <time_frame>Change from Baseline to Week 7</time_frame>
    <description>The STAI-Y2 Trait subscale consists of 20-item and will assess anxiety. The total score ranges from 20-80; higher scores indicate greater trait anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Posttraumatic Diagnostic Scale-5 (PDS-5)</measure>
    <time_frame>Change from Baseline to Week 7</time_frame>
    <description>The PDS-5 consists 24-item scale and will assess PTSD symptoms based on the diagnostic criteria for the DMS-5. The full PDS-5 assesses trauma history, symptom onset, and index of trauma. The total score ranges from 0-80.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Traumatic Stress Disorder</condition>
  <condition>Post Traumatic Stress Disorder</condition>
  <condition>Trauma and Stressor Related Disorders</condition>
  <condition>Mental Disorders</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>High Intensity Interval Training (HIIT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-intensity interval training will be performed three times a week for a total of six weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Waitlist participants were tested on the outcomes at the same time points as the treatment group (i.e., HIIT). Following completion of the waitlist treatment, participants will be eligible to receive a supervised exercise program (no data will be collected). The waitlist participants formed a no-treatment control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High Intensity Interval Training (HIIT)</intervention_name>
    <description>Twenty minutes of HIIT will be completed three days a week for six weeks.</description>
    <arm_group_label>High Intensity Interval Training (HIIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Waitlist</intervention_name>
    <description>Waitlist participants will be tested on the outcomes at the same time points as the treatment group.</description>
    <arm_group_label>Waitlist Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  self-reported exposure to a traumatic event&#xD;
&#xD;
          -  persistent (&gt; 1 month) PTSD-related symptoms adequate to screen positive for PTSD or&#xD;
             self-reported history of a prior PTSD diagnosed by a health care professional.&#xD;
&#xD;
          -  poor sleep quality (Pittsburgh Sleep Quality Index &gt;5)&#xD;
&#xD;
          -  failure to meet recommended level of aerobic or resistance training. Physical activity&#xD;
             for U.S. adults (&lt;150-mins of moderate or 75-mins of vigorous physical activity [or a&#xD;
             combination] per week and/or &lt; 2 days a week of resistance training targeting the&#xD;
             major muscle groups).&#xD;
&#xD;
          -  able to safely perform high-intensity exercise&#xD;
&#xD;
          -  aged 18-39 years&#xD;
&#xD;
          -  non-smoker&#xD;
&#xD;
          -  willing to avoid alcohol and vigorous physical activity 24 hours before visiting the&#xD;
             lab&#xD;
&#xD;
          -  willing to avoid caffeine for 12 hours before visiting the lab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, lactating, or plans to become pregnant over the next 2 months.&#xD;
&#xD;
          -  Individuals who started taking medication for anxiety or depression-related symptoms&#xD;
             within the last month.&#xD;
&#xD;
          -  Individuals currently taking beta-blockers or other medications/substances (marijuana&#xD;
             and other illegal drugs) that impact heart rate.&#xD;
&#xD;
          -  History of reproductive disorders (e.g., premenstrual dysphoric disorder or polycystic&#xD;
             ovary syndrome), cardiovascular (e.g., cardiac arrhythmia), or pulmonary disorders&#xD;
             (e.g., asthma).&#xD;
&#xD;
          -  Pain intensity of 8 or greater in the thigh or foot in the past month&#xD;
&#xD;
          -  Probable alcohol use disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J O'Connor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa J McGranahan, MS</last_name>
    <phone>8156669006</phone>
    <email>mmcg91@uga.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Georgia</investigator_affiliation>
    <investigator_full_name>Patrick O'Connor</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Trauma and Stressor Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT05097352/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT05097352/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

